Real-world study findings suggest that people with rheumatoid arthritis treated with the JAK inhibitor baricitinib may have a higher risk for venous thromboembolism than those on TNF inhibitors.

The Janus kinase inhibitor baricitinib has the potential to be “an important part of the treatment landscape” for juvenile arthritis, research suggests.

Discordant results from two phase 3 studies make it difficult to determine whether baricitinib benefits patients with systemic lupus erythematosus, despite previous positive findings in phase 2.

Findings from a phase 1/2 pilot study suggest that baricitinib may be a promising treatment option for primary Sjögren's syndrome.

“[T]he known and potential benefits of baricitinib when used to treat COVID-19 in such patients […] outweigh the known and potential risks,” the agency adds.

Patients with rheumatoid arthritis may derive better clinical outcomes from baricitinib than tofacitinib in the first 24 weeks of treatment, especially if they have previously received multiple biologic DMARDs, show real-world data.

Real-world study results suggest that the majority of baricitinib-treated patients with rheumatoid arthritis remain on the JAK inhibitor after a year, with older age and female sex associated with treatment persistence.

Adding the JAK inhibitor baricitinib to remdesivir treatment reduces recovery time and improves clinical outcomes in hospitalized patients with moderate-to-severe COVID-19, suggest findings from the ACTT-2 randomized controlled trial.

Adding the JAK inhibitor baricitinib to remdesivir treatment reduces recovery time and improves clinical outcomes in hospitalized patients with moderate-to-severe COVID-19, suggest findings from the ACTT-2 randomized controlled trial.

Adding the JAK inhibitor baricitinib to remdesivir treatment reduces recovery time and improves clinical outcomes in hospitalized patients with moderate-to-severe COVID-19, suggest findings from the ACTT-2 randomized controlled trial.

medwireNews : The US FDA has issued an Emergency Use Authorization permitting the use of the Janus kinase (JAK) inhibitor baricitinib, in combination with remdesivir, for the treatment of COVID-19.

Patients with moderate-to-severe rheumatoid arthritis treated with the JAK inhibitor baricitinib experience benefits for up to 3 years, researchers report.

Preliminary findings from an observational study suggest that add-on treatment with baricitinib may improve respiratory function in patients with moderate-to-severe SARS-CoV-2 pneumonia.

The JAK inhibitor baricitinib results in clinical improvements among Chinese patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate, suggests an analysis of data from the RA-BALANCE trial.

The US FDA has added a precaution to the label for baricitinib advising of a possible risk for reactions including angioedema, urticaria, and rash that may reflect drug hypersensitivity.

Brief interruptions are common among people receiving baricitinib for rheumatoid arthritis and are associated with minor increases in symptoms that resolve following retreatment without impacting long-term efficacy, phase 3 trial data show.

Baricitinib monotherapy may be a suitable maintenance strategy for some patients with rheumatoid arthritis, but some may also need methotrexate, suggest findings from a post-hoc analysis.

Analysis of data from the RA-BEAM and RA-BEYOND trials suggests that switching from adalimumab to baricitinib is associated with improvements in disease control and patient-reported outcomes in patients with rheumatoid arthritis, with an acceptable safety profile.

Analysis of data from the RA-BEAM and RA-BEYOND trials suggests that switching from adalimumab to baricitinib is associated with improvements in disease control and patient-reported outcomes in patients with rheumatoid arthritis, with an acceptable safety profile.

The addition of once-daily baricitinib to standard background therapy could improve clinical outcomes in patients with systemic lupus erythematosus, phase II trial findings show.